Anti-CoV-RBD (B6) antibody

Reference: PTXCOV-A521B



Product type


Description of Anti-CoV-RBD (B6) antibody

General information on Anti-CoV-RBD (B6) antibody

The receptor-binding domain (RBD) of the new strain of coronavirus, SARS-CoV-2, is considered by many experts as the key domain contributing to the high transmission rate of the COVID-19 disease. Thus, designing antibodies targeting this region became an essential step in controlling the on-going pandemic. Moreover, obtaining anti-CoV-RBD antibodies became crucial not only from a therapeutic point of view but also from a research point of view.
Despite the similarity between SARS-CoV, the etiological agent behind the 2003 pandemic, and SARS-CoV-2, significant differences were found between their respective binding domains. This could explain SARS-CoV-2 higher infectivity as well as its significantly faster spread among the world’s population. Further comparative studies between the two pandemic strains may prove useful for the design of more effective immunotherapies.
The anti-CoV-RBD (B6) antibody is a fully human IgG immunoglobulin derived from a complex COVID-19 human antibody library (LiAb-SFCOVID-19™). The library comprises the immune diversity of dozens of patients who have survived the COVID-19 disease; moreover, it is fully adapted for fast screening with phage display technologies. The affinity and specificity of this phage display-derived antibody were tested and validated with ELISA. Additionally, its SARS-CoV-2 neutralizing activity was further tested in vitro using a competition assay using recombinantly expressed RBD and human ACE2 receptor (SARS-CoV-2 Surrogate Virus Neutralization Test, sVNT). Lastly, the ease of expression and stability of the anti-CoV-RBD (B6) antibody was further confirmed by recombinant production in the transient mammalian system (XtenCHO™).
This antibody is thus a suitable reagent to aid in the efforts for better understanding the infection mechanisms of SARS-CoV-2. Moreover, it can be useful for epidemic surveillance and optimization of SARS-CoV-2 neutralizing reagents.

Product nameAnti-CoV-RBD (B6) antibody
Expression systemMammalian
Molecular weight150kDa
BufferPBS, pH7,5
Delivery conditionDry ice
Storage condition4°C for short term; -20°c or -80°C for long term
NoteFor research use and in vitro diagnostic only. Not suitable for human use.
ClonalityMonoclonal Antibody


There are no reviews yet.

Be the first to review “Anti-CoV-RBD (B6) antibody”

Your email address will not be published.



Please select the country of delivery so that we can send you the quotation including shipping costs.

Thank you for your request! You will receive your quotation per e-mail in a few seconds.

If you did not receive your quotation, please check your spam folder.

Contact us to order

+33 (0)3 90 20 54 70

Write us